Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Research

Pharmaceutical

Science

Biotechnology

Curatis Holding

More Like This

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01

Curatis discloses Corticorelin as active substance of C-PTBE-01

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients

Merus Receives FDA extension of PDUFA for zenocutuzumab

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene